Ibogaine: The Psychedelic Drug Explored for Addiction Treatment

Ibogaine, a powerful psychedelic substance, has gained attention following the death of model Presley Gerber at age 27. Gerber, who had been open about his struggles with addiction and mental health, reportedly used ibogaine in a bid to address these issues. His case has highlighted the ongoing exploration of ibogaine as a potential treatment for substance use disorders.

Ibogaine is derived from the root bark of the iboga shrub, native to Central and West Africa. Historically, indigenous communities have utilized it in spiritual and healing ceremonies. In the mid-20th century, it was briefly available in France as a stimulant and antidepressant before being banned. Around the same period, researchers began investigating its anti-addictive properties, prompted by anecdotal reports of its effectiveness in reducing opioid cravings and withdrawal symptoms.

Effects and Potential Benefits

When ingested, typically as a capsule or mixed with water, ibogaine induces prolonged psychedelic and dissociative effects. Users often experience vivid visions, followed by a deeply introspective phase. Researchers suggest that during this phase, the brain may become more receptive to forming new neural connections, potentially aiding in recovery from addiction. Dr. Kirsten Cherian, a Stanford University researcher, noted that ibogaine affects multiple neurotransmitter systems, which may contribute to its capacity for reorganizing brain networks. This neurological impact is thought to underlie some of the reported therapeutic benefits.

Studies have indicated ibogaine's potential in managing withdrawal symptoms and reducing cravings associated with substances like opioids, cocaine, and alcohol. A 2017 study involving participants with opioid dependence found that a significant portion reported reduced or no opioid use one month after treatment, with some maintaining abstinence for up to a year. Another study conducted in Mexico reported that a high percentage of individuals receiving ibogaine treatment experienced reduced opioid withdrawal symptoms and cravings, with a notable portion abstaining from opioids long-term. Research also suggests potential benefits for depression, anxiety, and traumatic brain injuries.

Risks and Legal Status

Despite its potential, ibogaine carries significant risks. While generally considered to have a low risk of addiction, it can cause dangerous side effects, including low blood pressure, seizures, respiratory distress, anxiety, and hallucinations. Irregular heart rhythms have also been linked to ibogaine use, and it has been associated with fatalities in medical literature. Experts emphasize that ibogaine must be administered in a controlled medical setting by trained professionals due to these risks.

In the United States, ibogaine is classified as a Schedule I controlled substance, meaning it is deemed to have a high potential for abuse and no accepted medical use. This classification has historically limited research into the drug.

Shifting Research Landscape

However, the regulatory landscape is beginning to shift. In April, the Food and Drug Administration (FDA) approved the first human clinical trial in the U.S. for an ibogaine derivative aimed at treating alcohol use disorder. This development followed an executive order signed by President Donald Trump aimed at expediting psychedelic research and increasing access for individuals with mental illness. The FDA has also provided priority review vouchers to companies developing psychedelic treatments for depression and PTSD, signaling a broader governmental interest in these therapies.

Federal agencies are now directed to expand research efforts, with funding allocated for clinical trials. The initial clinical trial will focus on noribogaine hydrochloride, a derivative developed by DemeRx NB, to assess its efficacy in treating alcohol use disorder, a condition affecting millions in the U.S. and contributing to preventable deaths.